نتایج جستجو برای: egfr mutation

تعداد نتایج: 315266  

Journal: :Journal of Thoracic Oncology 2022

EGFR-TKIs (tyrosine kinase inhibitor) can effectively improve the survival rate of NSCLC patients with EGFR sensitive mutations. However, concomitant alterations along mutations often affect effect EGFR-TKIs. The genome characteristic co-mutation is great significance for guiding clinical treatment. In this study, we first reported genetic characteristics EGFR/RB1/TP53 co-variation in Chinese n...

2014
Xiaohong Han Zhishang Zhang Di Wu Yinchen Shen Shuai Wang Lin Wang Yutao Liu Sheng Yang Xingsheng Hu Yun Feng Yan Sun Yuankai Shi

BACKGROUND Epidermal growth factor receptor (EGFR) mutation status is crucial in treatment selection for non-small cell lung cancer (NSCLC) patients; however, the detection materials' availability remains challenging in clinical practice. In this study, we collected surgical resection tissues, lymph node biopsy, and cytological samples for EGFR mutation testing and investigated the associations...

2016
Norikazu Matsuo Koichi Azuma Kazuko Sakai Satoshi Hattori Akihiko Kawahara Hidenobu Ishii Takaaki Tokito Takashi Kinoshita Kazuhiko Yamada Kazuto Nishio Tomoaki Hoshino

The most common event responsible for resistance to first- and second-generation (1st and 2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is acquisition of T790M mutation. We examined whether T790M is related to clinicopathologic or prognostic factors in patients with relapse of EGFR mutant non-small cell lung cancer (NSCLC) after treatment with 1st or 2nd EGFR-TKIs...

2017
Jin-Qiu Yuan Yue-Lun Zhang Hai-Tao Li Chen Mao

BACKGROUND Epidermal growth factor receptor (EGFR) mutation testing in tumor tissue is now a common practice in selecting non-small cell lung cancer (NSCLC) patients for EGFR tyrosine kinase inhibitor (TKI) treatment. However, tumor tissues are often absent or insufficient for the testing. Blood is a potential substitute providing a noninvasive, easily accessible and repeatedly measureable sour...

2015
BO ZHANG CHUN-WEI XU YUN SHAO HUAI-TAO WANG YONG-FANG WU YE-YING SONG XIAO-BING LI ZHE ZHANG WEN-JING WANG LI-QIONG LI CONG-LI CAI

Early detection of epidermal growth factor receptor (EGFR) mutation, particularly EGFR T790M mutation, is of clinical significance. The aim of the present study was to compare the performances of amplification refractory mutation system-based quantitative polymerase chain reaction (ARMS-qPCR) and droplet digital polymerase chain reaction (ddPCR) approaches in the detection of EGFR mutation and ...

2016
Yuan Feng Jihong Zhou Sining Chen Ying Jiang Ying Zhou

Lung cancer has the highest morbidity and mortality in malignant tumor worldwide. EGFR-TKI targeted therapy is a type of treatment with low side effects. However, it needs to clarify EGFR mutation status. Limited to sampling, EGFR mutation test cannot be widely applied. Finding other simple and practical markers to predict EGFR mutation state is of great significance. This study aimed to evalua...

Journal: :Lung cancer 2013
A Jasmijn Hubers Daniëlle A M Heideman Yasushi Yatabe Michelle D Wood Justyna Tull Miquel Tarón Miquel A Molina Clara Mayo Jordi Bertran-Alamillo Gerarda J M Herder Remco Koning Daoud Sie Bauke Ylstra Gerrit A Meijer Peter J F Snijders Birgit I Witte Pieter E Postmus Egbert F Smit Erik Thunnissen

OBJECTIVES Epidermal growth factor receptor (EGFR) mutations have been identified in lung adenocarcinomas and are associated with high response chance to EGFR tyrosine kinase inhibitors. EGFR mutations can be detected in tumour tissue, cytology specimens and blood from lung cancer patients. Thus far, EGFR mutation analysis has not been systematically demonstrated for sputum samples. The aim of ...

2012
Fei Xu Jingxun Wu Cong Xue Yuanyuan Zhao Wei Jiang Liping Lin Xuan Wu Yachao Lu Hua Bai Jiasen Xu Guanshan Zhu Li Zhang

BACKGROUND Previous studies have reported that epidermal growth factor receptor (EGFR) mutation in tumor tissue and peripheral blood can predict the response to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). However, the heterogeneity of the sample sources makes it difficult to evaluate the detecting methodologies. The goal of this study is to compare different meth...

2016
Shang-Gin Wu Yih-Leong Chang Chong-Jen Yu Pan-Chyr Yang Jin-Yuan Shih

To understand the impact of PIK3CA mutations on clinical characteristics and treatment response to epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) of lung adenocarcinoma, we examined PIK3CA and EGFR mutations in lung adenocarcinoma patients, and analyzed their clinical outcomes. Surgically excised tumor, bronchoscopy biopsy/brushing specimens and pleural effusions were prospectiv...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید